Detalles de la búsqueda
1.
Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells.
Cancer Immunol Immunother
; 73(3): 45, 2024 Feb 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38349430
2.
A novel multicolor fluorescent spot assay for the functional assessment of chimeric antigen receptor (CAR) T-cell products.
Cytotherapy
; 26(4): 318-324, 2024 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38340107
3.
The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.
Br J Haematol
; 195(3): 405-412, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34500492
4.
Toxoplasma-induced hemophagocytic lymphohistiocytosis after haploidentical allogeneic stem cell transplantation.
Transpl Infect Dis
; 22(2): e13242, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31895492
5.
Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell-depleted lymphoma after CART therapy.
Blood
; 140(2): 152-156, 2022 07 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35537186
6.
Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cells.
Haematologica
; 109(2): 682-688, 2024 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37675514
7.
Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and Ponatinib.
Acta Haematol
; 141(2): 107-110, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30695783
8.
Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation.
Blood
; 121(15): 2864-74, 2013 Apr 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-23426943
9.
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.
Blood
; 122(25): 4129-39, 2013 Dec 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-24055823
10.
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation.
Biol Blood Marrow Transplant
; 20(1): 4-13, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24018392
11.
Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation.
Blood
; 119(12): 2956-9, 2012 Mar 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-22289893
12.
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies.
Biol Blood Marrow Transplant
; 19(12): 1661-9, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24018393
13.
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation.
Biol Blood Marrow Transplant
; 19(11): 1537-45, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24018395
14.
Ocular adverse events associated with chimeric antigen receptor T-cell therapy: a case series and review.
Br J Ophthalmol
; 107(7): 901-905, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35144919
15.
Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD).
Hum Vaccin Immunother
; 19(2): 2216116, 2023 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37278257
16.
Outcomes of Busulfan, Fludarabine, and 400 cGy Total Body Irradiation Compared With Busulfan and Fludarabine Reduced-Intensity Conditioning Regimens for Allogeneic Stem Cell Transplantation in Adult Patients With Hematologic Diseases: A Single-Center Experience.
Transplant Proc
; 55(1): 214-224, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36635141
17.
Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by 18F-FDG PET/CT Imaging Following CAR-T Therapy.
Clin Lymphoma Myeloma Leuk
; 23(10): 757-763, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37453865
18.
Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial.
Transplant Cell Ther
; 29(3): 208.e1-208.e6, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36584941
19.
Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed/refractory diffuse large B-Cell lymphoma.
Leuk Lymphoma
; 63(6): 1339-1347, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35045791
20.
T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccine.
J Immunother Cancer
; 10(7)2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35851312